Literature DB >> 10810369

Simian virus 40: the link with human malignant mesothelioma is well established.

M Carbone1, P Rizzo, H Pass.   

Abstract

Mesotheliomas are malignancies of the pleural, pericardial, and peritoneal surfaces with a mean survival of less than 1 year from the time of diagnosis (1). While mesotheliomas were extremely rare in the first half of this century, the incidence of these tumors has increased enormously in the last several decades. Presently, 2-3 thousand people in the US develop and die of mesothelioma each year (1). It is estimated that approximately 80% of mesotheliomas develop in people with a history of occupational asbestos exposure or in individuals with family member(s) professionally exposed to asbestos that brought home fibers on their clothing (1). Although conventional wisdom dictates that asbestos is the most commonly associated "environmental" factor with mesothelioma, asbestos does not transform human mesothelioma cells in tissue culture (2). This suggests that additional carcinogens act in concert with asbestos to cause mesothelioma. Recent evidence indicated that Simian Virus 40 (SV40) preferentially causes mesotheliomas in hamsters, and that SV40 is present in up to 80% of human mesotheliomas in the US and in Europe (reviewed in ref. 3 and 4).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810369

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  23 in total

Review 1.  Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Authors:  Zhongjian Chen; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 2.  Mesothelioma: recent highlights.

Authors:  Michele Carbone; Haining Yang
Journal:  Ann Transl Med       Date:  2017-06

Review 3.  The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad.

Authors:  Salih A Emri
Journal:  Ann Transl Med       Date:  2017-06

4.  Municipal pleural cancer mortality in Spain.

Authors:  G López-Abente; V Hernández-Barrera; M Pollán; N Aragonés; B Pérez-Gómez
Journal:  Occup Environ Med       Date:  2005-03       Impact factor: 4.402

5.  Improving the Accuracy of Mesothelioma Diagnosis in China.

Authors:  Zhenying Guo; Michele Carbone; Xing Zhang; Dan Su; Wenyong Sun; Jianlin Lou; Zhibin Gao; Dichu Shao; Junqiang Chen; Gu Zhang; Jinlin Hu; Kaiyan Chen; Fang Wang; Harvey I Pass; Herbert Yu; Andrea Napolitano; Haining Yang; Weimin Mao
Journal:  J Thorac Oncol       Date:  2016-12-19       Impact factor: 15.609

Review 6.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Authors:  Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass
Journal:  CA Cancer J Clin       Date:  2019-07-08       Impact factor: 508.702

7.  Malignant deciduoid mesothelioma: a rare variant of epithelioid mesothelioma.

Authors:  Leah Taylor; David Cooper; Avinash Aujayeb
Journal:  BMJ Case Rep       Date:  2019-07-08

8.  SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma.

Authors:  P Cacciotti; R Libener; P Betta; F Martini; C Porta; A Procopio; L Strizzi; L Penengo; M Tognon; L Mutti; G Gaudino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

9.  Occurrence of TRGV-BJ hybrid gene in SV40-transformed fibroblast cell lines.

Authors:  L P G D'Arce; C L Bassi; A L Fachin; G A S Passos; E T Sakamoto-Hojo
Journal:  Genetica       Date:  2009-01-14       Impact factor: 1.082

Review 10.  Mesothelioma epidemiology, carcinogenesis, and pathogenesis.

Authors:  Haining Yang; Joseph R Testa; Michele Carbone
Journal:  Curr Treat Options Oncol       Date:  2008-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.